StockData

Yarrow Bioscience, Inc. (YARW) income statement

YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30105% above fair value
$14.23−0.12 (-0.84%)

Close on Nov 19, 2026Market cap $37.99MP/E –Yield –

Yarrow Bioscience, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
–
Operating margin
-5219.1%
Net margin
-4646.1%
Return on equity, FY2025
-66.3%

Financial strength

Current ratio
15.26
Debt to equity
–
Debt to assets
–
Cash to current liabilities
1486.7%

Valuation

P/E ratio
–
Price to sales
66.65
Price to book
1.72
Dividend yield
–

See a number that looks wrong?